Low Muscle Mass Linked to Higher Osteoporosis Risk in Type 2 Diabetes Patients

A large retrospective study of more than 12,000 hospitalized patients with type 2 diabetes has found that people with lower estimated skeletal muscle mass are markedly more likely to have clinically recorded osteoporosis, and that a simple laboratory-derived index of muscle mass can sharpen the accuracy of osteoporosis risk prediction in this vulnerable population. The research, published in BMC Endocrine Disorders, adds to a growing body of evidence that muscle and bone are not independent tissues but partners in a shared mechanical and metabolic dialogue, one that appears to falter in diabetes.

The study, led by Jinhua Chen of the Department of General Practice at Chengdu Integrated TCM & Western Medicine Hospital in China, enrolled 12,187 patients with type 2 diabetes who were hospitalized between 1 January 2018 and 31 December 2025. Rather than measuring bone density directly with dual-energy X-ray absorptiometry, the gold-standard imaging technique, the team identified osteoporosis through electronic medical records and tenth-revision International Classification of Diseases codes. In total, 718 participants, or 5.9 percent of the cohort, carried a documented osteoporosis diagnosis. The researchers then asked a deceptively simple question: did the amount of skeletal muscle a patient was predicted to carry, estimated from routine blood tests, track with the likelihood of that diagnosis?

The muscle metric at the heart of the study is the predicted skeletal muscle mass index, or pSMI. It belongs to a family of surrogate measures that exploit a well-established physiological relationship: creatinine, a waste product generated almost exclusively by muscle as it breaks down phosphocreatine to power contraction, is released into the bloodstream in rough proportion to muscle mass and then cleared by the kidneys. Cystatin C, by contrast, is produced by virtually all nucleated cells at a steady rate and is likewise cleared renally, but it is essentially indifferent to how much muscle a person has. Dividing creatinine by cystatin C therefore yields a ratio that rises with muscle mass while canceling out much of the kidney-function signal that would otherwise confound the picture. From this creatinine-to-cystatin C ratio, together with demographic and anthropometric variables, the investigators computed a predicted index of skeletal muscle mass for each patient.

Participants were sorted into three groups according to tertiles of the index, spanning values from 2.76 to 6.81 in the lowest group, 6.82 to 7.94 in the middle group, and 7.95 to 15.45 in the highest. The gradient in osteoporosis prevalence across these tiers was striking. In multivariate logistic regression models that progressively adjusted for age, sex, body mass index, blood pressure, glycated hemoglobin, lipid profile, kidney function, liver enzymes, and comorbidities, each one-unit increase in the predicted muscle index was associated with lower odds of documented osteoporosis. In the fully adjusted model, the odds ratio was 0.60, with a 95 percent confidence interval of 0.55 to 0.66 and a p-value below 0.001. Compared with patients in the lowest tertile, those in the highest had roughly a quarter of the odds of carrying an osteoporosis diagnosis, with an odds ratio of 0.23.

Crucially, the relationship was not a straight line. Using restricted cubic splines, a flexible modeling technique that lets the data describe their own shape rather than forcing a linear trend, the researchers found a statistically significant non-linear dose-response curve. This suggests that the protective association between muscle mass and bone health may be steepest in certain ranges of the index, a pattern with practical implications for deciding where clinical attention might yield the greatest benefit. The team also ran subgroup analyses that revealed significant effect modification by sex, body mass index, and hypertension status, with interaction p-values of 0.002, 0.003, and 0.02 respectively. In other words, the strength of the muscle-bone link differed meaningfully between men and women, between leaner and heavier patients, and between those with and without high blood pressure.

Beyond establishing association, the study probed whether the muscle index earns its place in a predictive model. In exploratory receiver operating characteristic analysis, adding pSMI to a baseline model of conventional risk factors lifted the area under the curve from 0.7705 to 0.7926, a modest but statistically significant improvement in discrimination. The optimal cut-off value for the index was 7.22, which achieved a sensitivity of 80.4 percent and a specificity of 57.1 percent. The researchers also turned to SHAP analysis, a machine-learning interpretability method rooted in cooperative game theory that assigns each variable a quantified contribution to individual predictions. In this framework, the predicted muscle index emerged as the second most important predictor of documented osteoporosis, trailing only age.

The biological logic connecting muscle to bone is compelling on several fronts. Mechanically, skeletal muscle is the dominant load applied to bone through tendons during everyday activity, and bone, following the principles of mechanotransduction, responds to mechanical strain by favoring formation over resorption. Weaker or smaller muscles deliver weaker osteogenic signals. Metabolically, muscle and bone engage in endocrine cross-talk: myokines such as irisin and interleukin-6 released during contraction influence osteoblast activity, while bone-derived osteocalcin has been implicated in energy metabolism. Diabetes complicates this partnership in multiple ways. Chronic hyperglycemia promotes the formation of advanced glycation end-products that stiffen collagen in both muscle and bone, insulin itself is anabolic to muscle, and diabetic complications including neuropathy and vascular disease can accelerate both sarcopenia and the fragile, poorly mineralized bone phenotype that characterizes diabetic osteoporosis.

The clinical appeal of the pSMI approach lies in its accessibility. Dual-energy X-ray absorptiometry scanners are expensive, stationary, and often unavailable in the primary care and inpatient settings where most patients with diabetes are actually managed. By contrast, serum creatinine and cystatin C are routinely ordered laboratory tests, meaning the index can be computed from data that already exist in the medical record. For hospitalized patients with type 2 diabetes, a population in which osteoporosis frequently goes undetected until a fracture occurs, a zero-cost screening signal derived from routine chemistry could meaningfully change the calculus of who gets referred for definitive bone density testing.

Yet the authors and the study design counsel caution. Because the analysis is cross-sectional, it captures a single moment in time and cannot establish whether low muscle mass precedes osteoporosis, follows it, or arises from shared upstream causes such as physical inactivity, inflammation, or poor glycemic control. The reliance on diagnostic codes and medical records rather than systematic DXA scanning means some cases of osteoporosis may have been missed, and the recorded prevalence of 5.9 percent likely understates the true burden in this population. The cohort consisted exclusively of hospitalized patients at a single Chinese hospital network, which limits generalizability to community-dwelling or outpatient populations. The modest size of the improvement in predictive discrimination, while statistically robust, also underscores that pSMI is a complement to, not a replacement for, established risk assessment.

Even with those caveats, the study offers a provocative glimpse of where metabolic medicine is heading. The convergence of routine biomarkers, machine-learning interpretability tools, and large electronic health record datasets is making it possible to extract clinically actionable signals from tests that clinicians order every day. If future longitudinal studies confirm that the predicted skeletal muscle mass index anticipates bone loss in diabetes, and if interventions that build muscle, from resistance training to nutritional optimization, are shown to protect bone in parallel, then a simple ratio of two blood proteins could become an early warning system for one of the most feared complications of diabetes. For now, the message from Chengdu is clear: in patients with type 2 diabetes, what the muscle knows, the bone seems to follow.

Subject of Research: Association between predicted skeletal muscle mass index and osteoporosis in patients with type 2 diabetes

Article Title: Cross-sectional association between predicted skeletal muscle mass index and osteoporosis in hospitalized patients with type 2 diabetes mellitus

Article References: Cross-sectional association between predicted skeletal muscle mass index and osteoporosis in hospitalized patients with type 2 diabetes mellitus. (n.d.). https://doi.org/10.1186/s12902-026-02602-6

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02602-6

Keywords: type 2 diabetes, osteoporosis, skeletal muscle mass, sarcopenia, creatinine-to-cystatin C ratio, bone health, logistic regression, SHAP analysis, risk prediction, endocrinology, retrospective study, diabetic complications